111 related articles for article (PubMed ID: 27479828)
1. Comparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations.
Faqeer NA; Mashni O; Dawoud R; Rumman A; Hanoun E; Nazer L
J Clin Pharmacol; 2017 Feb; 57(2):275-279. PubMed ID: 27479828
[TBL] [Abstract][Full Text] [Related]
2. Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.
Poirier E; Desbiens C; Poirier B; Hogue JC; Lemieux J; Doyle C; Leblond AF; Côté I; Cantin G; Provencher L
Ann Pharmacother; 2014 Apr; 48(4):447-55. PubMed ID: 24321851
[TBL] [Abstract][Full Text] [Related]
3. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
[TBL] [Abstract][Full Text] [Related]
4. Febrile neutropenia incidence and the variable toxicity profile between brand and generic docetaxel in the adjuvant treatment of breast cancer with docetaxel and cyclophosphamide regimen.
Tarcha FV; Baccarin ALC; Barros LADR; Alencar EBA; Del Giglio A; Cruz FJSM
Einstein (Sao Paulo); 2023; 21():eAO0486. PubMed ID: 38126660
[TBL] [Abstract][Full Text] [Related]
5. Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration.
Lee CF; Zhou K; Young WM; Wong CS; Ng TY; Lee SF; Leung K; Wong LKM; So KH; Tang W; Chong G; Chan SK; Yip YTE; Ma VYM; Yeung A; Chin CHY; Kwan MW; Tsang HT
Support Care Cancer; 2020 Aug; 28(8):3801-3812. PubMed ID: 31832822
[TBL] [Abstract][Full Text] [Related]
6. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
7. Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel.
Peltekian S; Sajwani S; Wang X; Kanji S
Support Care Cancer; 2023 May; 31(5):311. PubMed ID: 37126153
[TBL] [Abstract][Full Text] [Related]
8. Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer.
Tagawa N; Sugiyama E; Tajima M; Sasaki Y; Nakamura S; Okuyama H; Shimizu H; Sato VH; Sasaki T; Sato H
Cancer Chemother Pharmacol; 2017 Oct; 80(4):841-849. PubMed ID: 28864856
[TBL] [Abstract][Full Text] [Related]
9. A Difference in the Incidences of Hypersensitivity Reactions to Original and Generic Taxanes.
Ratanajarusiri T; Sriuranpong V; Sitthideatphaiboon P; Poovoravan N; Vinayanuwat C; Parinyanitikul N; Angspatt P; Thawinwisan W; Tanasanvimon S
Chemotherapy; 2017; 62(2):134-139. PubMed ID: 27997900
[TBL] [Abstract][Full Text] [Related]
10. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
[TBL] [Abstract][Full Text] [Related]
11. Incidence and Clinical Outcomes of Febrile Neutropenia in Adult Cancer Patients with Chemotherapy Using Korean Nationwide Health Insurance Database.
Kim D; Lee S; Youk T; Hong S
Yonsei Med J; 2021 Jun; 62(6):479-486. PubMed ID: 34027634
[TBL] [Abstract][Full Text] [Related]
12. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer.
Aagaard T; Reekie J; Jørgensen M; Roen A; Daugaard G; Specht L; Sengeløv H; Mocroft A; Lundgren J; Helleberg M
Cancer Med; 2020 May; 9(9):3033-3042. PubMed ID: 32144897
[TBL] [Abstract][Full Text] [Related]
13. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
15. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.
Wang L; Barron R; Baser O; Langeberg WJ; Dale DC
Value Health; 2014 Sep; 17(6):739-43. PubMed ID: 25236998
[TBL] [Abstract][Full Text] [Related]
16. Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer.
Matsui A; Morise M; Tanaka I; Ozone S; Matsuzawa R; Koyama J; Hase T; Hashimoto N; Sato M; Hasegawa Y
Cancer Invest; 2020 Aug; 38(7):424-430. PubMed ID: 32643445
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
18. The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.
Fujiwara T; Kenmotsu H; Naito T; Kawamura T; Mamesaya N; Kotake M; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Taira T; Murakami H; Omae K; Mori K; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1229-1237. PubMed ID: 28455585
[TBL] [Abstract][Full Text] [Related]
19. [Generic drugs controversy in oncology].
Levêque D; Becker G; Gourieux B
Bull Cancer; 2017 Jun; 104(6):497-499. PubMed ID: 28495129
[No Abstract] [Full Text] [Related]
20. Differences between the quality aspects of various generic and branded docetaxel formulations.
Yiding C; Zhongyi H
Curr Med Res Opin; 2021 Aug; 37(8):1421-1433. PubMed ID: 33998944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]